CTOs on the Move

BioMarin

www.biomarin.com

 
BioMarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. We remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. These patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. Time is critical to patients with ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.biomarin.com
  • 770 Lindaro Street
    San Rafael, CA USA 94901
  • Phone: 415.506.6700

Executives

Name Title Contact Details
Shilpa Shroff
Executive Director of Technology Development for Process Science Profile
Robert Baffi
President of Global Manufacturing and Technical Operations Profile
Chris Houlder
Senior Director, Global CyberSecurity Profile
David Shiao
Director - Information Technology Security and Compliance Profile

Funding

BioMarin raised $720M on 08/10/2016

Similar Companies

Becton Dickinson and Company

Becton Dickinson and Company is a Sandy, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioLife Solutions

BioLife Solutions is a leading supplier of cell and gene therapy bioproduction tools.

ACT Services

ACT Services is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vaxart

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immuno-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Verve Therapeutics

Verve Therapeutics is a biotechnology company focused on discovering and developing therapies that safely edit the genomes of adults to confer lifelong protection against coronary artery disease, the most common type of heart disease and the leading cause of death worldwide. Headquartered in Cambridge, Mass., with a research facility in Philadelphia.